107 related articles for article (PubMed ID: 17213971)
1. [PTHrP and bone sialoprotein as prognostic markers for developing bone metastases in breast cancer patients].
Loibl S; Königs A; Kaufmann M; Costa SD; Bischoff J
Zentralbl Gynakol; 2006 Dec; 128(6):330-5. PubMed ID: 17213971
[TBL] [Abstract][Full Text] [Related]
2. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis.
Diel IJ; Solomayer EF; Seibel MJ; Pfeilschifter J; Maisenbacher H; Gollan C; Pecherstorfer M; Conradi R; Kehr G; Boehm E; Armbruster FP; Bastert G
Clin Cancer Res; 1999 Dec; 5(12):3914-9. PubMed ID: 10632320
[TBL] [Abstract][Full Text] [Related]
3. Polymerase chain reaction analysis of parathyroid hormone-related protein gene expression in breast cancer patients and occurrence of bone metastases.
Bouizar Z; Spyratos F; Deytieux S; de Vernejoul MC; Jullienne A
Cancer Res; 1993 Nov; 53(21):5076-8. PubMed ID: 8221637
[TBL] [Abstract][Full Text] [Related]
4. [Detection of disseminated carcinoma cells in bone marrow and peripheral blood in primary breast cancer with RT/PCR of parathyroid hormone-related protein (PTHrP)].
Liersch T; Gatzemeier W; Scharnberg P; Jürgens B; Wörmann B; Becker H; Rauschecker HF; Hiddemann W; Wulf GG
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):277-80. PubMed ID: 14518259
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors for skeletal relapse in breast cancer.
Diel IJ
Cancer Treat Rev; 2001 Jun; 27(3):153-7; discussion 159-64. PubMed ID: 11417965
[TBL] [Abstract][Full Text] [Related]
6. Bone sialoprotein is predictive of bone metastases in resectable non-small-cell lung cancer: a retrospective case-control study.
Papotti M; Kalebic T; Volante M; Chiusa L; Bacillo E; Cappia S; Lausi P; Novello S; Borasio P; Scagliotti GV
J Clin Oncol; 2006 Oct; 24(30):4818-24. PubMed ID: 17050866
[TBL] [Abstract][Full Text] [Related]
7. The parathyroid hormone-related protein (PTHrP) gene: use of downstream TATA promotor and PTHrP 1-139 coding pathways in primary breast cancers vary with the occurrence of bone metastasis.
Bouizar Z; Spyratos F; De vernejoul MC
J Bone Miner Res; 1999 Mar; 14(3):406-14. PubMed ID: 10027905
[TBL] [Abstract][Full Text] [Related]
8. Parathyroid hormone-related protein localization in breast cancers predict improved prognosis.
Henderson MA; Danks JA; Slavin JL; Byrnes GB; Choong PF; Spillane JB; Hopper JL; Martin TJ
Cancer Res; 2006 Feb; 66(4):2250-6. PubMed ID: 16489028
[TBL] [Abstract][Full Text] [Related]
9. Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma.
Woitge HW; Pecherstorfer M; Horn E; Keck AV; Diel IJ; Bayer P; Ludwig H; Ziegler R; Seibel MJ
Br J Cancer; 2001 Feb; 84(3):344-51. PubMed ID: 11161399
[TBL] [Abstract][Full Text] [Related]
10. Expression of bone matrix proteins in human breast cancer: potential roles in microcalcification formation and in the genesis of bone metastases.
Bellahcène A; Castronovo V
Bull Cancer; 1997 Jan; 84(1):17-24. PubMed ID: 9180854
[TBL] [Abstract][Full Text] [Related]
11. Potential use of tumour marker CA 15-3 in the staging and prognosis of patients with breast cancer.
Horobin JM; Browning MC; McFarlane NP; Smith G; Preece PE; Wood RA; Cuschieri A
J R Coll Surg Edinb; 1991 Aug; 36(4):219-21. PubMed ID: 1941734
[TBL] [Abstract][Full Text] [Related]
12. Prognostic role of serum cancer antigen 15-3 in breast cancer patients with isolated bone metastases.
Turanli S; Cetin A
Biomarkers; 2010 Aug; 15(5):418-23. PubMed ID: 20441435
[TBL] [Abstract][Full Text] [Related]
13. Parathyroid hormone-related protein, bone metastases and hypercalcaemia of malignancy.
Bundred NJ; Walls J; Ratcliffe WA
Ann R Coll Surg Engl; 1996 Jul; 78(4):354-8. PubMed ID: 8712650
[TBL] [Abstract][Full Text] [Related]
14. Parathyroid hormone related protein in breast cancers of widely varying prognosis.
Kissin MW; Henderson MA; Danks JA; Hayman JA; Bennett RC; Martin TJ
Eur J Surg Oncol; 1993 Apr; 19(2):134-42. PubMed ID: 8491317
[TBL] [Abstract][Full Text] [Related]
15. Postoperative PINP in serum reflects metastatic potential and poor survival in node-positive breast cancer.
Jukkola A; Bloigu R; Holli K; Joensuu H; Valavaara R; Risteli J; Blanco G
Anticancer Res; 2001; 21(4B):2873-6. PubMed ID: 11712779
[TBL] [Abstract][Full Text] [Related]
16. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
[TBL] [Abstract][Full Text] [Related]
17. Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development.
Bellahcene A; Kroll M; Liebens F; Castronovo V
J Bone Miner Res; 1996 May; 11(5):665-70. PubMed ID: 9157781
[TBL] [Abstract][Full Text] [Related]
18. Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites.
Powell GJ; Southby J; Danks JA; Stillwell RG; Hayman JA; Henderson MA; Bennett RC; Martin TJ
Cancer Res; 1991 Jun; 51(11):3059-61. PubMed ID: 2032246
[TBL] [Abstract][Full Text] [Related]
19. Polyadenylate polymerase enzymatic activity in mammary tumor cytosols: A new independent prognostic marker in primary breast cancer.
Scorilas A; Talieri M; Ardavanis A; Courtis N; Dimitriadis E; Yotis J; Tsiapalis CM; Trangas T
Cancer Res; 2000 Oct; 60(19):5427-33. PubMed ID: 11034084
[TBL] [Abstract][Full Text] [Related]
20. Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers.
Waltregny D; Bellahcène A; de Leval X; Florkin B; Weidle U; Castronovo V
J Bone Miner Res; 2000 May; 15(5):834-43. PubMed ID: 10804012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
